DCM
CTNM

Driehaus Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Driehaus Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,667
Closed -$1.28M – 461
2024
Q3 		$1.28M Hold
66,667
– – 0.01% 312
2024
Q2 		$1.17M Buy
+66,667
New +$1.07M 0.01% 300

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

Driehaus Capital Management's CTNM Position: Q4 2024 in Review

Driehaus Capital Management sold out of Contineum Therapeutics (CTNM) in Q4 2024, closing a stake of 66,667 shares — an estimated $1.28M sold.

Driehaus Capital Management first reported a position in CTNM in Q2 2024 and held it in 2 quarters. The position peaked at $1.28M in Q3 2024. 62 funds tracked by Wall St. Rank hold CTNM as of Q4 2024.

  • Driehaus Capital Management reported no remaining Contineum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Driehaus Capital Management sold 66,667 Contineum Therapeutics shares in Q4 2024, an estimated $1.28M.
  • Driehaus Capital Management first reported a position in Contineum Therapeutics in Q2 2024 and held it in 2 quarters.
  • Driehaus Capital Management's Contineum Therapeutics position peaked at $1.28M in Q3 2024.
  • 62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2024.

Based on Driehaus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.